Form D · Biotechnology
Tvardi Therapeutics, Inc.
Houston, TX · CIK 0001742947
Offering snapshot reported Jun 16, 2021 · SEC filing
- Reported sold
- $72.4M Offering amount: $75.1M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 16, 2021 | Initial | $72,418,254 | No comparison | Not reported | SEC filing |
| Jul 30, 2018 | Amendment | $5,649,659 | $2,500,001vs Jun 8, 2018 | 8 | SEC filing |
| Jun 8, 2018 | Initial | $3,149,658 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-403053
Source: Form D, filed Jun 16, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Imran Alibhai | Director, Executive |
| Ronald De Pinho | Director |
| Wallace Hall | Director |
| Jamie Mc Nab | Director |
| Sujal Shah | Director |
| David J. Tweardy | Director, Executive |
| Michael Wyzga | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2450 Holcombe Boulevard Suite X
Houston, TX, 77021
Houston, TX, 77021